SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is experiencing intense volatility as shareholders push for leadership changes and express frustration over slumping sales, high inventory levels, and a perceived disconnection from modern consumer trends. The market is deeply divided ahead of its earnings release, with a significant cohort of traders actively shorting the stock, while others view its recent descent to multi-year lows as a potential, though highly risky, entry point for a long-term turnaround.

BRC Group Holdings, Inc. engages in the provision of financial services and solutions to the capital raising and financial advisory needs of public and private firms. It operates through the following segments: Capital Markets, Wealth Management, Financial Consulting, Auction and Liquidation, Communications, and Consumer. The Capital Markets segment provides investment banking, corporate finance, research, wealth management, and sales and trading services to corporate, institutional, and high net worth clients. The Wealth Management segment offers retail brokerage, investment management, and insurance, and tax preparation services. The Financial Consulting segment focuses on a variety of specialized advisory services spanning bankruptcy, restructuring, turnaround management, forensic accounting, crisis and litigation support, appraisal and valuation, real estate, and operations management. The Auction and Liquidation segment deals with retail liquidation services. The Communications segment is composed of a portfolio of companies acquired for attractive risk-adjusted investment return characteristics. The Consumer segment includes Targus and the Brands investment portfolio. The company was founded in 1973 and is headquartered in Los Angeles, CA.

BRC Group Holdings Inc.

B. Riley Financial Inc

B. Riley Financial is trending as investors gear up for the upcoming 10-K filing and earnings report, with the community closely tracking the company's aggressive debt reduction efforts and the performance of key holdings like Applied Digital and BW. Bullish sentiment remains high as retail participants anticipate a potential valuation re-rating driven by balance sheet improvements and a possible short squeeze.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors monitor the early commercial rollout of Yartemlea and anticipate further clarity on revenue ramp and European regulatory progress. The community remains focused on potential milestone payments from the partnership with Novo Nordisk and the company's long-term potential as a commercial-stage biotech, despite current frustration over recent share price volatility and limited official guidance.

RH operates as a holding company which operates the business through its subsidiary Restoration Hardware, Inc. It offers furniture, lighting, textiles, bath ware, decor, outdoor and garden, as well as baby and child products. The company operates an integrated business with multiple channels of distribution including galleries, source books and websites. The company was founded by Stephen J. Gordon in 1980 and is headquartered in Corte Madera, CA.

RH - Ordinary Shares - Class A

Restoration Hardware

Restoration Hardware is experiencing significant volatility as investors weigh the company's exposure to ongoing tariff risks against its ambitious international expansion and long-term luxury strategy. The community remains deeply divided, with some traders betting on a short squeeze or a valuation recovery, while others express skepticism over the firm's leadership and the sustainability of its high-end furniture pricing in a strained economic environment.

THE FAMOUS DOG JUMPING INTO THE WATER FROM TIKTOK WITH 500M+ VIEWS.  A few facts about me - Signature Pool Dive - Serial Killer - Silly  Roadmap 1. BORN - Launch of a token, development of a family of holders and a twitter 2.BORN - Project development, marketing and connect KOLs 3. CEX listings - Listing on top exchanges and partnerships  Being a memecoin doesn’t mean we won’t have utilities. Our developers will develop some fun and useful tools for its community members as we continue to BUIDL! Our main goal is to make sure everyone has access to our utilities, so we build it with scalability in mind.  Ready to Splash?

Splash Dog

BUSTER CRYPTO is gaining momentum within the Solana ecosystem as community members rally behind the token and express strong bullish sentiment regarding its growth potential.

"What's Updog?" is a Community Led token.

UpDog

The UpDog community is driving significant engagement through a coordinated social campaign to increase visibility and brand awareness. Discussions are largely centered around community building, frequent meme-style interaction, and encouraging new participants to join their ecosystem.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is facing intense community scrutiny and volatility as investors weigh the company's long-term promise in photonics against a lack of concrete revenue milestones ahead of upcoming financial reports. While bulls point to high-profile ecosystem partnerships and potential for massive scaling by 2027, bears remain focused on the company's history of dilution and the absence of significant, publicly disclosed production orders, keeping market sentiment cautious.

Tema ETF Trust - Tema Space Innovators ETF

Investors are gaining exposure to the broader space economy through this newly listed ETF, with community discussions centering on its strategic holdings in key industry players and comparisons to other space-focused stocks.

Dave & Buster's Entertainment, Inc. engages in the ownership and operation of entertainment and dining venues under the name Dave & Buster's. It offers a full menu of entrées and appetizers, a selection of alcoholic and non-alcoholic beverages, and an assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The company was founded by David O. Corriveau and James W. Corley in 1982 and is headquartered in Coppell, TX.

Dave & Buster`s Entertainment Inc

Dave & Buster's Entertainment

Dave & Buster's is facing significant scrutiny as the community highlights recent health code violations, including a vermin infestation, alongside ongoing debates about the company's financial sustainability and weakening competitive position against at-home entertainment. Investors are actively discussing the stock's high short interest and its potential for volatility, with many expressing skepticism about management's turnaround strategy amidst poor operational performance.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is facing significant selling pressure and volatility, closing its worst quarter since 2008 amid investor concerns regarding AI-related capital expenditures and broader software market weakness. While the community remains divided on whether the stock is a long-term buy at current oversold levels, many are actively debating the impact of the ongoing geopolitical conflict and recent leadership shifts within the Copilot division.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>In a mid-stage study, alixorexton demonstrated statistically significant, clinically meaningful and dose-dependent improvements from baseline compared to placebo in wakefulness.</li><li>RBC Capital said the Lilly-Centessa deal highlights large pharma interest in the sleep space and "underscores what could likely be a large indication," which is "favorable" for Alkermes.</li><li>Leerink, who has a ‘Market Perform’ rating on Alkermes shares, opined that the stock could attract interest from large pharma companies seeking a presence in sleep disorders.</li></ul>Shares of Alkermes Plc (ALKS) rallied 15% on Tuesday after pharmaceutical giant Eli Lilly and Company reached an agreement to acquire its peer Centessa for up to $7.8 billion.Centessa is developing a pipeline of orexin receptor 2 (OX2R) agonists to treat excessive daytime sleepiness and disorders of impaired wakefulness. Its lead investigational candidate cleminorexton is under development to treat narcolepsy type 1, narcolepsy type 2, and idiopathic hypersomnia.Alkermes, meanwhile, is also developing an orexin 2 receptor for narcolepsy called alixorexton. In a mid-stage study, alixorexton demonstrated statistically significant, clinically meaningful and dose-dependent improvements from baseline compared to placebo in wakefulness. Alkermes plans to initiate the alixorexton narcolepsy global phase 3 program in early 2026.<h2 class="st-heading-2">Wall Street Weighs In</h2>RBC Capital said the Lilly-Centessa deal highlights large pharma interest in the sleep space and "underscores what could likely be a large indication," which is "favorable" for Alkermes. The firm, which thinks Alkermes' current share price is undervaluing the orexin program alone given comps, notwithstanding the profitable core business, has an ‘Outperform’ rating and $45 price target on the shares.Leerink, who has a ‘Market Perform’ rating on Alkermes shares, opined that the stock could attract interest from large pharma companies seeking a presence in sleep disorders.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around ALKS stock rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume increased from ‘low’ to ‘normal’ levels.<a href="https://stocktwits.com/symbol/ALKS">ALKS stock</a> has gained 5% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-rallies-in-anticipation-of-upbeat-q1-delivery-numbers-after-america-expansion-efforts/cZE5cWMRIVp">Nio Stock Rallies In Anticipation Of Upbeat Q1 Delivery Numbers After America Expansion Efforts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Alkermes logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

ALKS Stock Surges 15% On Lilly-Centessa Buyout Igniting Sleep Pipeline Hopes

Alkermes, like Centessa, is also developing an orexin 2 receptor for narcolepsy called alixorexton.

Equity

Alkermes, like Centessa, is also developing an orexin 2 receptor for narcolepsy called alixorexton.


Alkermes (NASDAQ:ALKS) Shares Gap Up - Still a Buy?

Alkermes (NASDAQ:ALKS) Shares Gap Up - Should You Buy...

Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday

US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave...

Alkermes plc (NASDAQ:ALKS) Receives Consensus Rating of "Moderate Buy" from Analysts

Alkermes plc (NASDAQ:ALKS - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eighteen brokerages that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, four have assi...

Tudor Investment Corp ET AL Acquires New Position in Alkermes plc $ALKS

Tudor Investment Corp ET AL acquired a new stake in shares of Alkermes plc (NASDAQ:ALKS - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange...

Why Is Alkermes (ALKS) Down 2.6% Since Last Earnings Report?

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alkermes (NASDAQ:ALKS) Stock Rating Upgraded by Truist Financial

Truist Financial upgraded shares of Alkermes to a "strong-buy" rating in a research note on Wednesday...

Piper Sandler Issues Pessimistic Forecast for Alkermes (NASDAQ:ALKS) Stock Price

Piper Sandler cut their price target on shares of Alkermes from $45.00 to $43.00 and set an "overweight" rating on the stock in a report on Tuesday...

Alkermes CEO Pops Calls 2026 a Really Exciting Year as Orexin Agonists Near Narcolepsy Launch

Alkermes (NASDAQ:ALKS) CEO Richard Pops said the company is entering what he described as a really exciting year as the orexin agonist field moves closer to commercialization in narcolepsy, with...

Holocene Advisors LP Cuts Holdings in Alkermes plc $ALKS

Holocene Advisors LP lowered its stake in Alkermes plc (NASDAQ:ALKS - Free Report) by 13.5% during the third quarter, according to its most recent 13F filing with the Securities and Exchange...

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Alkermes plc

Sprott Silver Miners & Physical Silver ETF ($SLVR)

Tradr 2x Long Innovation 100 Monthly ($MQQQ)

GraniteShares Autocallable NVDA ETF ($ANV)

Direxion Daily ASML Bull 2x ($ASMU)

The ultimate tool for the active trader. This award goes to the fund that helped traders master the market—whether by protecting against risks or jumping on the latest trends to capture quick wins.

Current Price	$35.36
Prev Close	$30.15
Open	$32.96
Dividend Yield	0.00%
50-Day Moving Average	$31.25
Beta	0.59
Avg. Volume	1.86M
PE Ratio	21.05

52-Week High	$36.32
52-Week Low	$25.17
Market Capitalization	$5.02B
EPS (Annual)	$1.43
Price to Book	2.74
Revenue Per Employee	$719,950.73

ALKS
Alkermes plc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ALKS News

ALKSAlkermes plc